January 8, 2015
Otsuka Pharmaceutical Co., Ltd.
Terminations of Otsuka's Contract With OncoTherapy Science, Inc. on a Candidate Therapeutic Vaccine for Pancreatic Cancer and Otsuka's Sublicensing Contract With Fuso Pharmaceutical Industries for the Marketing of a Candidate Therapeutic Vaccine, OTS102
Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announces that the exclusive licensing contract that has been in effect with OncoTherapy Science, Inc. (OTS) for the development, manufacture, and marketing of a peptide therapeutic vaccine for the treatment of pancreatic cancer, will be allowed to expire, following 180-day prior notification, at the scheduled end date of the contract period. A sublicensing contract which has been in effect with Fuso Pharmaceutical Industries, Ltd. for the manufacture and marketing in Japan of OTS102, a therapeutic vaccine, will also be allowed to expire on the same date.
Otsuka will continue its efforts in oncology as a priority area. This will include the development of the peptide therapeutic vaccine OCV-C02, for which a phase 1 clinical study is currently underway in colon cancer based on a contract with OTS.
Information in this news release was current as of the original release date.